reslizumab vs mepolizumab | 合法藥品大搜索
由DPHenriksen著作·2018·被引用30次—Efficacy,adverseevents,andinter-drugcomparisonofmepolizumabandreslizumabanti-IL-5treatmentsofsevereasthma-asystematicreview ...,由IAgache著作·2020·被引用57次—Efficacyandsafetyoftreatmentwithbiologicals(benralizumab,dupilumab,mepolizumab,omalizumabandreslizumab)forsevereeosinophilicasthma.A ...,由KYan著作·2019·被引用4次—Materials&methods:Eligiblestudiesevaluatedreslizumabandmepolizumabinpatientswithinadequately-controlledsevereeosinophilicast ...,由MLidda...
dupilumab vs mepolizumab Mepolizumab benralizumab benralizumab vs dupilumab benralizumab vs omalizumab nucala vs fasenra vs dupixent benralizumab review xolair and dupixent combination EAACI biologicals Guidelines recommendations for severe asthma Mepolizumab benralizumab健保 benralizumab中文 benralizumab機轉 mepolizumab健保 Mepolizumab benralizumab omalizumab健保 nucala健保價 利兒精液 維他命d3缺乏 維他命d3懷孕 適汎黴素功效 適汎黴素膀胱炎 皮爽下架 補鐵保健食品推薦ptt 利多卡因軟膏
Efficacy, adverse events, and inter | 合法藥品大搜索
由 DP Henriksen 著作 · 2018 · 被引用 30 次 — Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review ... Read More
Efficacy and safety of treatment with biologicals ... | 合法藥品大搜索
由 I Agache 著作 · 2020 · 被引用 57 次 — Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A ... Read More
Reslizumab and mepolizumab for moderate | 合法藥品大搜索
由 K Yan 著作 · 2019 · 被引用 4 次 — Materials & methods: Eligible studies evaluated reslizumab and mepolizumab in patients with inadequately-controlled severe eosinophilic ast ... Read More
Higher Binding Affinity and in vitro Potency of Reslizumab for ... | 合法藥品大搜索
由 M Liddament 著作 · 2019 · 被引用 15 次 — Reslizumab and mepolizumab are recently approved monoclonal antibodies for the treatment of severe (uncontrolled) eosinophilic asthma. Both are effective in ... Read More
Mabs for treating asthma | 合法藥品大搜索
由 E Ridolo 著作 · 2020 · 被引用 3 次 — They include monoclonal antibodies that target the Th2-pathway cytokines, such as IL-5 (mepolizumab and reslizumab) or its receptor ( ... Read More
Weight | 合法藥品大搜索
由 M Mukherjee 著作 · 2018 · 被引用 118 次 — ... IV reslizumab was superior to fixed-dose SC mepolizumab in ... of Δ between before and after treatment, mepolizumab vs. reslizumab, ... Read More
Efficacy, adverse events, and inter-drug ... | 合法藥品大搜索
由 DP Henriksen 著作 · 2018 · 被引用 30 次 — Conclusions: Mepolizumab and reslizumab provide significant and clinically relevant improvements in exacerbation rate and OCS reduction. Read More
Reslizumab and mepolizumab for moderate | 合法藥品大搜索
由 K Yan 著作 · 2019 · 被引用 4 次 — Reslizumab and mepolizumab are anti-IL5 biologics for the treatment of severe eosinophilic asthma. No head-to-head comparisons of the relative ... Read More
Mepolizumab | 合法藥品大搜索
2017年9月21日 — By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab, reslizumab and benralizumab are new 'anti-IL-5' ... Read More
Efficacy and safety of treatment with biologicals (benralizumab ... | 合法藥品大搜索
由 I Agache 著作 · 2020 · 被引用 57 次 — Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic ... Read More
相關資訊整理
【舒肺樂注射劑100毫克/毫升】嚴重氣喘之維持治療：表現型為嗜伊紅性白血球的嚴重氣喘且控制不良(severe refractory eosinophilic asthma)之12歲以上病人之附加維持治療。嗜伊紅性肉芽腫併多發性血管炎：治療嗜伊紅性肉芽腫併多發性血管炎[eosinophilic granulomatosis with polyangiitis (EGPA)]之成人病人。
藥品名稱:舒肺樂注射劑100毫克/毫升許可證字號:衛部菌疫輸字第001144號許可證種類:菌 疫適應症:嚴重氣喘之維持治療：表現型...
【舒肺樂凍晶注射劑】1.嚴重氣喘之維持治療表現型為嗜伊紅性白血球的嚴重氣喘且控制不良(severe refractory eosinophilic asthma)之6歲以上病人之附加維持治療。2.嗜伊紅性肉芽腫併多發性血管炎：治療嗜伊紅性肉芽腫併多發性血管炎[eosinophilic granulomatosis with polyangiitis (EGPA)]之成人病人。
藥品名稱:舒肺樂凍晶注射劑許可證字號:衛部菌疫輸字第001015號許可證種類:菌 疫適應症:1.嚴重氣喘之維持治療表現型為嗜伊紅...
【肺昇朗注射液劑30毫克】FASENRA適用於嗜酸性白血球表現型的嚴重氣喘成人病人，做為附加維持治療。
藥品名稱:肺昇朗注射液劑30毫克許可證字號:衛部菌疫輸字第001101號許可證種類:菌 疫適應症:FASENRA適用於嗜酸性白血球表現...